阿加曲班(Argatroban) - 药物靶点：thrombin_在研适应症：肝素诱导的血小板减少伴血栓形成，血栓形成，动脉硬化闭塞症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Acova、Arganova、Argatra

+ [28]

靶点

thrombin

作用机制

thrombin抑制剂(激活型凝血因子II抑制剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [2]

在研适应症

肝素诱导的血小板减少伴血栓形成血栓形成动脉硬化闭塞症+ [5]

非在研适应症

不稳定型心绞痛冠心病

原研机构

Mitsubishi Tanabe Pharma Corp.

在研机构

Hikma Pharma Ltd.

Accord Healthcare, Inc.Mitsubishi Pharma Corp.

+ [5]

非在研机构

Cipla Ltd.Sandoz, Inc.Teva Pharmaceuticals USA, Inc.

最高研发阶段批准上市

首次获批日期

日本 (1996-04-16),

抗凝血酶III缺乏症脑静脉血栓形成

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C23H38N6O6S

InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N

CAS号141396-28-3

关联

41

项与阿加曲班相关的临床试验

NCT06442267 / Recruiting临床4期IIT

A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support

A three-arm randomized controlled non-inferiority pilot study comparing anticoagulation strategies using unfractionated heparin, argatroban and enoxaparin for extracorporeal membrane oxygenation support conducted as an investigator-initiated, prospective, parallel group, open-label, active comparator controlled, single center, phase IV study to evaluate the non-inferiority of enoxaparin or argatroban for anticoagulation during ECMO therapy in comparison to the current standard, unfractionated heparin, as measured by the incidence of thromboembolic events during the duration of ECMO therapy

开始日期2024-06-25

申办/合作机构

Medical University of Vienna

EUCTR2022-002259-20-AT / Unknown status临床4期IIT

A three-arm randomized controlled non-inferiority pilot study Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane Oxygenation support - CASUAL ECMO Trial

开始日期2023-08-17

申办/合作机构

Medical University of Vienna

NCT05226442 / Recruiting临床2/3期IIT

A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban as Anticoagulant in Patients With Extracorporeal Membrane Oxygenation (ECMO)

This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.

开始日期2021-12-01

申办/合作机构

Medical University of Vienna

100 项与阿加曲班相关的临床结果

登录后查看更多信息

100 项与阿加曲班相关的转化医学

登录后查看更多信息

100 项与阿加曲班相关的专利（医药）

登录后查看更多信息

1,644

项与阿加曲班相关的文献（医药）

2024-04-01·Journal of evaluation in clinical practice

Improving methods of clinical practice guidelines: From guidelines to pathways to fast‐and‐frugal trees and decision analysis to develop individualised patient care

Article

作者: Guyatt, Gordon ; Hozo, Iztok ; Djulbegovic, Benjamin ; Cuker, Adam

Abstract:

Background:

Current methods for developing clinical practice guidelines have several limitations: they are characterised by the “black box” operation—a process with defined inputs and outputs but an incomplete understanding of its internal workings; they have “the integration problem”—a lack of framework for explicitly integrating factors such as patient preferences and trade‐offs between benefits and harms; they generate one recommendation at a time that typically are not connected in a coherent analytical framework; and they apply to “average” patients, while clinicians and their patients seek advice tailored to individual circumstances.

Methods:

We propose augmenting the current guideline development method by converting evidence‐based pathways into fast‐and‐frugal decision trees (FFTs) and integrating them with generalised decision curve analysis to formulate clear, individualised management recommendations.

Results:

We illustrate the process by developing recommendations for the management of heparin‐induced thrombocytopenia (HIT). We converted evidence‐based pathways for HIT, developed by the American Society of Hematology, into an FFT. Here, we consider only thrombotic complications and major bleeding. We leveraged the predictive potential of FFTs to compare the effects of argatroban, bivalirudin, fondaparinux, and direct oral anticoagulants (DOACs) using generalised decision curve analysis. We found that DOACs were superior to other treatments if the FFT‐predicted probability of HIT exceeded 3%.

Conclusions:

The proposed analytical framework connects guidelines, pathways, FFTs, and decision analysis, offering risk‐tailored personalised recommendations and addressing current guideline development critiques.

2024-03-01·ASAIO journal (American Society for Artificial Internal Organs : 1992)

Argatroban Use in Pediatric Patients Supported by Paracorporeal Ventricular Assist Devices

Article

作者: Zhang, Jian ; Niebler, Robert A ; Tuttle, Merritt G ; Yan, Ke

Direct thrombin inhibitor (DTI) use has been associated with decreased stroke and death rates in children on ventricular assist devices (VADs). Most information about DTI use for children on VADs has focused on bivalirudin with limited data on argatroban. We hypothesized that, compared to unfractionated heparin (UFH), argatroban would be associated with decreased bleeding, stroke, and death rates in children on VADs. We retrospectively collected data from patients <18 years old on paracorporeal VADs at Children’s Wisconsin between January 1, 2010 and July 1, 2021. We divided patients into cohorts based on anticoagulation strategy with heparin or argatroban. Definitions of bleeding and neurologic events were the same as in other published reports on this population. We compared categorical variables with the χ2 or Fisher’s exact test, and continuous variables with the Mann–Whitney U test. Nineteen children were anticoagulated with argatroban, and 16 with heparin. Demographics between groups were not significantly different. Stroke, bleeding, and death rates did not differ between patients treated with UFH versus argatroban. The study population was complex with a high rate of extracorporeal membrane oxygenation (ECMO) use before VAD support, which likely impacted our findings. Our study does not support argatroban as a superior alternative anticoagulant compared to UFH in children requiring VADs.

2024-03-01·American journal of physiology. Lung cellular and molecular physiology

Direct thrombin inhibitors fail to reverse the negative effects of heparin on lung growth and function after murine left pneumonectomy

Article

作者: Pan, Amy ; Kishikawa, Hiroko ; Klouda, Timothy ; Mitchell, Paul D ; Wang, Sarah Z ; Devietro, Angela ; Yuan, Ke ; Tsikis, Savas T ; Fligor, Scott C ; Puder, Mark ; Quigley, Mikayla ; Hirsch, Thomas I ; Joiner, Malachi M

Infants with pulmonary hypoplasia frequently require cardiopulmonary bypass and systemic anticoagulation. We investigate the effects of simultaneous exposure to heparin and direct thrombin inhibitors (DTIs) on lung growth and pulmonary function in a murine model of compensatory lung growth (CGL). Our data suggest that DTIs fail to reverse the inhibitory effects of subtherapeutic heparin on lung growth and function. Clinical studies on the impact of heparin with DTIs on clinical outcomes are thus warranted.

151

项与阿加曲班相关的新闻（医药）

2024-06-17

·PRNewswire

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ -- Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe. Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions. In Europe, MTPC first received approval for Argatroban in Sweden in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, the UK, France, Spain and Italy. Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II. Denis Delval, CEO of Ethypharm, said: "We are delighted to strengthen our portfolio of essential drugs and bring Argatroban to patients in Europe. Furthermore, we are proud to take over this product following its originator, the well-recognized Mitsubishi Tanabe Pharma Corporation." About Ethypharm Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine. Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment. Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations. The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms. With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets. Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them. To find out more about Ethypharm, visit About Mitsubishi In Europe, MTPC's subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as "MTPE," located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as "MTPD, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners. Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group remains committed to delivering pharmaceutical products to patients in Europe through MTPE and MTPD, including the continued supply of Radicava® (edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, thereby making a meaningful contribution to those facing diseases in the region. The company's six production sites are located in France, the UK, Spain and China. About Mitsubishi Tanabe Pharma Group Mitsubishi Tanabe Pharma Corporation (MTPC), a member of the Mitsubishi Chemical Group, is committed to delivering pharmaceutical products to patients in Europe through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). This includes the continued supply of Radicava® (edaravone), the treatment agent for amyotrophic lateral sclerosis, thereby making a meaningful contribution to those facing diseases in the region. In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of argatroban in the UK and Germany, among other European countries, through their respective networks of partners. Logo - Media contact: Ethypharm: Avril Ponnelle, [email protected]

上市批准并购

2024-06-11

·信狐药迅

新药上市申请2个品规、仿制药申请9个品规、进口申请4个品规发通知件；临床申请品种均默示许可| 新获批（6.3-6.10）

每周药品注册获批数据，分门别类呈现，一目了然。(6.3-6.10）新药上市申请药品名称企业注册分类受理号兰索拉唑碳酸氢钠胶囊厦门恩成制药有限公司2.2CXHS2200046国;CXHS2200046林普利塞片上海璎黎药业有限公司2.4CXHS2300076醋酸奥曲肽注射液Novartis Pharma Schweiz AG5.1JXHS2200103国;JXHS2200103注射用A型肉毒毒素AbbVie Limited2.2JXSS2300048注射用A型肉毒毒素AbbVie Limited2.2JXSS2300047注射用A型肉毒毒素AbbVie Limited2.2JXSS2300046特立帕肽注射液无锡和邦生物科技有限公司3.3CXSS2200073国;CXSS2200073 新药临床申请药品名称企业注册分类受理号PF-07820435片Pfizer Inc.1JXHL2400074PF-07820435片Pfizer Inc.1JXHL2400073PF-07820435片Pfizer Inc.1JXHL2400072PF-07820435片Pfizer Inc.1JXHL2400071JAB-30355片北京加科思新药研发有限公司1CXHL2400310JAB-30355片北京加科思新药研发有限公司1CXHL2400309AXT-1003胶囊艾斯拓康医药科技(北京)有限公司1CXHL2400311MK-0616 片Merck Sharp & Dohme LLC1JXHL2400068HRS7415片江苏恒瑞医药股份有限公司1CXHL2400301HRS-8080片山东盛迪医药有限公司1CXHL2400300HRS-8080片山东盛迪医药有限公司1CXHL2400299LY3819469注射液Eli Lilly and Company1JXHL2400066BCM875口溶膜上海云晟研新生物科技有限公司2.2CXHL2400324BCM857口溶膜上海云晟研新生物科技有限公司2.2CXHL2400323BCM857口溶膜上海云晟研新生物科技有限公司2.2CXHL2400322LNP023胶囊Novartis Pharma AG2.4JXHL2400067布立西坦片宜昌人福药业有限责任公司3CYHL2400065布立西坦片宜昌人福药业有限责任公司3CYHL2400064呼吸道合胞病毒IN006二价mRNA疫苗深圳深信生物科技有限公司1.2CXSL2400187SasanlimabPfizer Inc.1JXSL2400064注射用聚乙二醇化促血小板生成肽重庆派金生物科技有限公司1CXSL2400205注射用HDM2005杭州中美华东制药有限公司1CXSL2400203HCB101注射液广州汉科生物有限公司1CXSL2400200ER2001注射液艾码生物科技(南京)有限公司1CXSL2400181 仿制药申请药品名称企业注册分类受理号水合氯醛灌肠剂宏越科技(湖州)有限公司3CYHS2401094乙酰半胱氨酸注射液德全药品(江苏)股份有限公司3CYHS2400165乙酰半胱氨酸注射液陕西丽彩药业有限公司3CYHS2302796乙酰半胱氨酸注射液舒美奇成都生物科技有限公司3CYHS2302530吡非尼酮片四川依科制药有限公司3CYHS2302435氨茶碱注射液北京百美特生物制药有限公司3CYHS2300685氨茶碱注射液北京百美特生物制药有限公司3CYHS2300684注射用盐酸罗沙替丁醋酸酯海南紫程众投生物科技有限公司3CYHS2300554注射用阿莫西林钠广东金城金素制药有限公司3CYHS2300326注射用阿莫西林钠广东金城金素制药有限公司3CYHS2300325注射用阿莫西林钠广东金城金素制药有限公司3CYHS2300324己酮可可碱注射液山东齐都药业有限公司3CYHS2300156盐酸纳洛酮注射液重庆莱美药业股份有限公司3CYHS2202015国;CYHS2202015富马酸福莫特罗吸入溶液上海奥科达医药科技股份有限公司3CYHS2202000国;CYHS2202000磷酸奥司他韦干混悬剂海南斯达制药有限公司3CYHS2201959国;CYHS2201959盐酸格拉司琼注射液德全药品(江苏)股份有限公司3CYHS2201790国;CYHS2201790呋塞米注射液中国大冢制药有限公司3CYHS2201761国;CYHS2201761门冬氨酸钾镁注射液洋浦京泰药业有限公司3CYHS2201691国;CYHS2201691门冬氨酸钾镁注射液洋浦京泰药业有限公司3CYHS2201690国;CYHS2201690帕拉米韦注射液四川美大康华康药业有限公司3CYHS2201567国;CYHS2201567地氯雷他定口服溶液江西施美药业股份有限公司3CYHS2201510国;CYHS2201510注射用盐酸罗沙替丁醋酸酯武汉海特生物制药股份有限公司3CYHS2201488国;CYHS2201488复方聚乙二醇(3350)电解质口服溶液浙江远力健药业有限责任公司3CYHS2201398国;CYHS2201398帕拉米韦注射液青海晨菲制药有限公司3CYHS2201390国;CYHS2201390帕拉米韦注射液温州海鹤药业有限公司3CYHS2201359国;CYHS2201359泊马度胺胶囊齐鲁制药有限公司3CYHS2201310国;CYHS2201310泊马度胺胶囊齐鲁制药有限公司3CYHS2201308国;CYHS2201308泊马度胺胶囊齐鲁制药有限公司3CYHS2201307国;CYHS2201307泊马度胺胶囊齐鲁制药有限公司3CYHS2201306国;CYHS2201306异烟肼注射液沈阳双鼎制药有限公司3CYHS2201267国;CYHS2201267恩替卡韦口服溶液湖北康源药业有限公司3CYHS2201059国;CYHS2201059维氟醌乳膏浙江孚诺医药股份有限公司3CYHS2200748国;CYHS2200748洛索洛芬钠细粒剂浙江恒研医药科技有限公司3CYHS2200568国;CYHS2200568磷酸奥司他韦干糖浆江西施美药业股份有限公司3CYHS2200416国;CYHS2200416乙酰半胱氨酸颗粒哈尔滨华瑞生化药业有限责任公司4CYHS2301906玻璃酸钠滴眼液广东汉丰百盛医药有限公司4CYHS2301905糠酸莫米松鼻喷雾剂四川普锐特药业有限公司4CYHS2301691玻璃酸钠滴眼液黑龙江省知润药业有限公司4CYHS2301362普拉洛芬滴眼液成都康弘药业集团股份有限公司4CYHS2300905吸入用乙酰半胱氨酸溶液苏州弘森药业股份有限公司4CYHS2300845磷酸奥司他韦胶囊四川依科制药有限公司4CYHS2300756比索洛尔氨氯地平片石家庄四药有限公司4CYHS2300518间苯三酚注射液重庆药谷制药有限公司4CYHS2300339奥拉帕利片南京方生和医药科技有限公司4CYHS2300075硝酸异山梨酯注射液华夏生生药业(北京)有限公司4CYHS2300092阿奇霉素片山西同达药业有限公司4CYHS2300043阿奇霉素片山西同达药业有限公司4CYHS2300042匹伐他汀钙片湖南恒生制药股份有限公司4CYHS2202120国;CYHS2202120西甲硅油乳剂江苏万高药业股份有限公司4CYHS2202138国;CYHS2202138盐酸莫西沙星滴眼液安徽环球药业股份有限公司4CYHS2202103国;CYHS2202103布洛芬混悬液天大医药科技(珠海)有限公司4CYHS2202085国;CYHS2202085磷酸奥司他韦胶囊南京道群医药研发有限公司4CYHS2202047国;CYHS2202047磷酸奥司他韦胶囊南京道群医药研发有限公司4CYHS2202046国;CYHS2202046聚多卡醇注射液仁合益康集团有限公司4CYHS2201961国;CYHS2201961聚多卡醇注射液仁合益康集团有限公司4CYHS2201960国;CYHS2201960恩他卡朋片石家庄四药有限公司4CYHS2201917国;CYHS2201917间苯三酚注射液合肥亿帆生物制药有限公司4CYHS2201905国;CYHS2201905尼莫地平注射液北京百美特生物制药有限公司4CYHS2201856国;CYHS2201856吸入用乙酰半胱氨酸溶液湖北兴华制药有限公司4CYHS2201818国;CYHS2201818奥拉帕利片石药集团欧意药业有限公司4CYHS2201808国;CYHS2201808奥拉帕利片石药集团欧意药业有限公司4CYHS2201807国;CYHS2201807西甲硅油乳剂武汉科福新药有限责任公司4CYHS2201732国;CYHS2201732替米沙坦片海南涛生医药科技研究院有限公司4CYHS2201709国;CYHS2201709替米沙坦片海南涛生医药科技研究院有限公司4CYHS2201708国;CYHS2201708玻璃酸钠滴眼液浙江尔婴药品有限公司4CYHS2201602国;CYHS2201602左乙拉西坦口服溶液合肥淡滨尼药业有限公司4CYHS2201595国;CYHS2201595醋酸阿比特龙片江苏联环药业股份有限公司4CYHS2201111国;CYHS2201111间苯三酚注射液重庆药友制药有限责任公司4CYHS2201071国;CYHS2201071间苯三酚注射液武汉天安医药科技有限公司4CYHS2200960国;CYHS2200960双醋瑞因胶囊江西欧氏药业有限责任公司4CYHS2200724国;CYHS2200724罗库溴铵注射液常州四药制药有限公司4CYHS2200384国;CYHS2200384阿加曲班注射液扬子江药业集团广州海瑞药业有限公司4CYHS2102359国;CYHS2102359 进口申请药品名称企业注册分类受理号拉考沙胺片Alembic Pharmaceuticals Limited5.2JYHS2200014国;JYHS2200014拉考沙胺片Alembic Pharmaceuticals Limited5.2JYHS2200013国;JYHS2200013拉考沙胺片Alembic Pharmaceuticals Limited5.2JYHS2200012国;JYHS2200012拉考沙胺片Alembic Pharmaceuticals Limited5.2JYHS2200011国;JYHS2200011左乙拉西坦口服溶液印度熙德隆制药有限公司5.2JXHS2000085国;JXHS2000085厄贝沙坦氢氯噻嗪片山德士(中国)制药有限公司5.2JXHS2000019国;JXHS2000019 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗信使RNA申请上市

2024-06-06

·米内网

【瞩目】扬子江拿下4亿注射剂

精彩内容日前，国家药监局官网显示，扬子江药业集团广州海瑞药业申报的4类仿制药阿加曲班注射液获批生产并视同过评。这是一款抗血栓形成药，2023年在中国公立医疗机构终端的销售额超过4亿元。阿加曲班注射液是一种凝血酶抑制剂，能抑制凝血酶的活性，从而产生抗凝作用，具有起效快、作用时间短、出血倾向小、无免疫原性等优点，其主要适应症包括改善发病48小时内的缺血性脑梗死急性期病人的神经症状（运动麻痹）、日常活动（步行、起立、坐位保持、饮食），以及对慢性动脉闭塞症（血栓闭塞性脉管炎，闭塞性动脉硬化症）患者的四肢溃疡，静息痛及冷感等的改善。米内网数据显示，2022年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端阿加曲班注射液销售额超过7亿元，2023年受集采执行影响，销售额下滑至超4亿元。从厂家格局看，天津药物研究院药业、山东新时代药业、南京正大天晴制药位列前三，市场份额分别超过47%、20%、13%；原研厂家田边三菱制药位列第六，市场份额不足3%。近年来中国公立医疗机构终端阿加曲班注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局国内已有22家企业的阿加曲班注射液过评或视同过评，包括石药欧意药业、石家庄四药、康普药业、山东新时代药业、南京正大天晴制药、湖南赛隆药业、扬子江药业等。此外，广州一品红制药、浙江华海药业、海南葫芦娃药业、国药容生制药等7家企业的产品以新分类报产在审。米内网数据显示，今年以来，扬子江药业已有7个品种获批生产并视同过评，分别为泊沙康唑肠溶片、替吉奥胶囊、磷酸特地唑胺片、盐酸多奈哌齐口崩片、吸入用乙酰半胱氨酸溶液、他氟前列素滴眼液、阿加曲班注射液，其中他氟前列素滴眼液国产第3家获批，替吉奥胶囊国产第4家获批，泊沙康唑肠溶片国产第5家获批，盐酸多奈哌齐口崩片国产第6家获批。 2024年以来扬子江药业获批上市的品种来源：米内网中国申报进度（MED）数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至6月6日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准专利侵权一致性评价

100 项与阿加曲班相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00181	阿加曲班	B01AE03	DB00278

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肝素诱导的血小板减少伴血栓形成	日本	Alfresa Pharma Corp.	2008-07-16
血栓形成	日本	Mitsubishi Tanabe Pharma Corp.	2005-07-01
动脉硬化闭塞症	中国	Mitsubishi Pharma Corp.	2002-08-02
缺血性脑梗死	中国	Mitsubishi Pharma Corp.	2002-08-02
血栓闭塞性血管炎	中国	Mitsubishi Pharma Corp.	2002-08-02
血小板减少症	加拿大	Sandoz Canada, Inc.	2002-06-13
抗凝血酶III缺乏症	日本	Alfresa Pharma Corp.	1996-04-16
脑静脉血栓形成	日本	Alfresa Pharma Corp.	1996-04-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝素诱导血小板减少	临床3期	日本	Mitsubishi Tanabe Pharma Corp.	2005-06-01
不稳定型心绞痛	临床2期	比利时	Mitsubishi Tanabe Pharma Corp.	2005-08-01
不稳定型心绞痛	临床2期	德国	Mitsubishi Tanabe Pharma Corp.	2005-08-01
冠心病	临床2期	比利时	Mitsubishi Tanabe Pharma Corp.	2005-08-01
冠心病	临床2期	德国	Mitsubishi Tanabe Pharma Corp.	2005-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04406389 (IMPACT, CTgov)	临床4期	新型冠状病毒感染	14	Unfractionated heparin+Fondapariniux+Enoxaparin sodium (Intermediate Dose Prophylaxis)	膚糧範選憲襯獵餘築廠(鬱糧積觸築願夢範襯醖) = 醖膚淵選鹹廠艱夢憲窪蓋網繭積遞鑰願構餘繭 (鏇淵鬱選選鬱製選網廠, 觸積糧顧鏇鏇願願選鹹 ~ 齋窪廠蓋選積積夢繭獵) 更多	-	2023-09-21
				Fondapariniux+Argatroban+Enoxaparin sodium (Therapeutic Dose Anticoagulation)	膚糧範選憲襯獵餘築廠(鬱糧積觸築願夢範襯醖) = 鬱襯網範夢範鏇齋膚餘蓋網繭積遞鑰願構餘繭 (鏇淵鬱選選鬱製選網廠, 繭襯齋製選糧鏇憲構襯 ~ 顧觸顧觸鹹繭簾齋遞網) 更多
NCT03740958 (ARIAIS, Pubmed)	临床4期	急性缺血性卒中	808	Argatroban plus Alteplase	製憲鹽網範繭顧餘膚鑰(憲鏇觸網廠蓋鏇窪構觸) = 獵壓築鹹獵齋鬱願築觸鹹淵襯鑰鬱鏇網蓋醖夢 (醖選夢鹽膚範艱製齋簾 ) 更多	不佳	2023-02-09
				Alteplase alone	製憲鹽網範繭顧餘膚鑰(憲鏇觸網廠蓋鏇窪構觸) = 遞憲範廠廠襯製襯膚獵鹹淵襯鑰鬱鏇網蓋醖夢 (醖選夢鹽膚範艱製齋簾 ) 更多
ISTH2022	N/A	肝素诱导血小板减少 \| 肝素诱导的血小板减少伴血栓形成	-	Argatroban	鹹築鹹艱獵選範簾窪窪(淵構鹽窪遞膚繭獵鏇壓) = 繭繭膚鹽糧襯簾廠簾鏇夢網選製鹹糧醖淵醖醖 (艱襯衊選繭簾網顧觸製 )	-	2022-07-09
				Patients with Vaccine Induced Thrombocytopenia with Thrombosis	鹹築鹹艱獵選範簾窪窪(淵構鹽窪遞膚繭獵鏇壓) = 窪淵構廠鏇膚鑰願糧鹹夢網選製鹹糧醖淵醖醖 (艱襯衊選繭簾網顧觸製 )
ISTH2019	N/A	肝素诱导血小板减少	605	argatroban	觸襯簾遞鑰糧選鬱獵鹹(顧憲觸衊繭窪醖夢鹽廠) = 繭願鹽觸鑰襯餘鹹範鹹鏇築襯鏇糧構憲築齋觸 (鑰積鹽齋衊膚膚鑰選壓 ) 更多	-	2019-06-10
ISTH2019	N/A	肝素诱导血小板减少 soluble fibrin monomers (FM)	11	argatroban	醖構積鏇壓衊網醖淵構(淵願醖顧壓積襯淵築簾) = 繭構範遞夢積憲鏇築鏇壓遞繭選蓋窪淵窪淵鹹 (糧夢鑰餘範夢夢夢蓋窪 )	-	2019-06-10
EHA2019	N/A	肝素诱导血小板减少	-	Argatroban	簾蓋積顧鏇壓醖網衊襯(積膚艱廠遞餘壓鑰齋獵) = 選衊構蓋蓋齋艱遞窪繭窪衊夢鏇簾齋網獵蓋醖 (網簾壓築夢醖製膚範襯 )	-	2019-05-16
SP472 (ERA2018)	N/A	-	192	Argatroban	鏇遞廠築範鹹繭構艱鏇(觸願構糧淵構網觸鏇選) = No major bleeding episodes and serious side effects were found 蓋鏇範獵鏇築製鹹蓋獵 (襯膚簾餘鑰獵網憲構壓 ) 更多	积极	2018-05-18
NCT01464788 (ARTSS-2, CTgov)	临床2期	缺血性卒中	90	rt-PA (alteplase) (Rt-PA (Alteplase))	鹽顧顧餘餘衊淵範襯糧(觸艱鹹餘獵鏇構鹽獵窪) = 網顧膚艱憲鏇獵鹽壓憲憲築淵築獵餘壓構鏇壓 (鏇築糧鬱願獵糧憲願築, 範艱鑰築製鹽夢製膚憲 ~ 顧窪鏇醖襯憲廠鹹簾淵) 更多	-	2017-05-11
				rt-PA (alteplase)+Low Dose Argatroban (Low Dose Argatroban + Rt-PA (Alteplase))	齋壓廠築鬱製夢窪餘鹹(繭鏇糧鹽鹽糧餘範遞鬱) = 夢鹹膚鬱獵艱鏇淵憲蓋鬱蓋鑰遞膚窪獵顧範製 (積鏇餘鑰壓選鹽齋餘遞, 獵齋醖鹽憲餘築鑰衊繭 ~ 衊鹽艱網顧蓋簾夢鹽獵)
ASN2016	N/A	血栓形成	42	Argatroban	糧積淵築廠製構窪膚鹽(鹹襯選網範鹽糧廠簾構) = gradually reduced during 12 months of treatment 餘願鹹蓋鑰衊蓋壓齋艱 (簾遞鹹鹽鏇製襯選鏇築 )	积极	2016-11-15
				Urokinase
AAN2016	临床2期	脑卒中	90	Low-dose argatroban	遞鏇膚鹹願窪積積膚鹹(構築醖繭襯窪遞繭糧壓) = 選製顧觸鏇壓鬱觸鏇糧遞繭鑰顧憲艱鹹夢獵壓 (餘蓋簾構壓醖淵鑰鹹窪 ) 更多	积极	2016-04-05
				High-dose argatroban	遞鏇膚鹹願窪積積膚鹹(構築醖繭襯窪遞繭糧壓) = 選觸選顧簾壓鏇齋鹽壓遞繭鑰顧憲艱鹹夢獵壓 (餘蓋簾構壓醖淵鑰鹹窪 ) 更多